A Phase 3 interventional study of MEDI4736 (Durvalumab) and MEDI4736 (Durvalumab)+Tremelimumab in Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca. Active, not recruiting at 196 sites in 17 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 7 that started in 2015, is one of 17 in phase 3, reaches primary completion later than 0 of the 36 other live ones, and was the 12th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Australia, Austria, Belgium and 7 more countries
Ages 18+
Idris Bahce · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 62 · Phase 3 17 · Phase 4 2
First in 2013; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,118 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 94 interventional studies. Of the 47 that completed or were terminated, 27 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 94 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 8th largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2015, is one of 44 in phase 3, reaches primary completion later than 1 of the 77 other live ones, and was the 76th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
8 of the studies testing durvalumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04465968Phase 3National Cancer Center Hospital EastEfficacy and Safety of CRT, Durvalumab and Surgery for SST | 2027-08-31 |
| NCT03965468ETOP IBCSG Partners FoundationImmunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | 2026-12 |
| NCT04245514Swiss Cancer InstituteMultimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | 2026-12-07 |
| NCT06908070Idris BahceChemoradiotherapy With Surgery Followed by Consolidation Durvalumab | 2026-12-17 |
| NCT05206812Yonsei UniversityWindow of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC
Patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 + tremelimumab combination therapy, MEDI4736 monotherapy, or Standard of Care (SoC) therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For inclusion in the study, patients should fulfill the following criteria:
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-L1 monoclonal Antibody monotherapy.
Biological: MEDI4736 (Durvalumab)
PD-L1+Tremelimumab combination therapy
Biological: MEDI4736 (Durvalumab)+Tremelimumab · Biological: Tremelimumab
Standard of Care chemotherapy treatment
Drug: Paclitaxel + Carboplatin · Drug: Gemcitabine + Cisplatin · Drug: Gemcitabine + Carboplatin · Drug: Pemetrexed + Cisplatin · Drug: Pemetrexed + Carboplatin
Drug page: Durvalumab
Drug pages: Paclitaxel · Carboplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Gemcitabine · Cisplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Gemcitabine · Carboplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Pemetrexed · Cisplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Pemetrexed · Carboplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy
The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
Time frame: From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
OS; PD-L1 (TC >=1%) Analysis Set Population
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
Time frame: From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
OS; FAS Population
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
Time frame: From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
PFS; PD-L1 (TC >=1%) Analysis Set Population
The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
PFS; FAS Population
The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population
The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of Complete Response (CR) or Partial Response (PR). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
ORR; PD-L1 (TC >=1%) Analysis Set Population
The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
ORR; FAS Population
The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population
The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
DoR; PD-L1 (TC >=1%) Analysis Set Population
The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
DoR; FAS Population
The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population
The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.
Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.
Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population
The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.
Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.
Percentage of Participants APF12; FAS Population
The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.
Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.
Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.
Time frame: Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).
PFS2; PD-L1 (TC >=1%) Analysis Set Population
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.
Time frame: Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).
PFS2; FAS Population
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.
Time frame: Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).
Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months
Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items with higher scores representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change is defined as an absolute change in the score from baseline of \>=10.
Time frame: At baseline then every 4 weeks for the first 8 weeks relative to the date of randomization, then every 8 weeks until second progression/death, whichever comes first. Assessed up to 12 months.
Serum Concentrations of Durvalumab
Blood samples were collected to determine the serum concentration of durvalumab.
Time frame: Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, and at follow-up Month 3.
Serum Concentrations of Tremelimumab
Blood samples were collected to determine the serum concentration of tremelimumab.
Time frame: Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3.
Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab
Blood samples were collected to determine the Cmax\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.
Time frame: Within 1 hour after end of infusion on infusion day at Week 12.
Cmax_ss of Tremelimumab
Blood samples were collected to determine the Cmax\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.
Time frame: Within 1 hour after end of infusion on infusion day at Week 12.
Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab
Blood samples were collected to determine the Ctrough\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose at Week 12.
Ctrough_ss of Tremelimumab
Blood samples were collected to determine the Ctrough\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose at Week 12.
Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against durvalumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
Time frame: At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.
Number of Participants With ADA Response to Tremelimumab
Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against tremelimumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
Time frame: At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.
A total of 194 centers across 17 countries in Asia, Australia, Europe and North America randomized adults with epidermal growth factor receptor and anaplastic lymphoma kinase wild-type advanced or metastatic non-small cell lung cancer in this study. First participant was randomized on 14 August 2015 and final data cut-off date was 04 October 2018.
| Milestone | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| Started | 374 | 372 | 372 |
| Received treatment | 369 | 371 | 352 |
| Completed | 0 | 0 | 0 |
| Not completed | 374 | 372 | 372 |
| Withdrew: Death | 275 | 277 | 296 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 12 | 10 | 11 |
| Withdrew: Participants ongoing at data cut-off | 85 | 84 | 62 |
| Withdrew: Other | 1 | 1 | 1 |
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy | 16.3 (12.2 to 20.8) | 11.9 (9.0 to 17.7) | 12.9 (10.5 to 15.0) |
The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.
| months | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|
| Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy | 3.9 (2.8 to 5.0) | 5.4 (4.6 to 5.8) |
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy | 16.3 (12.2 to 20.8) | 11.9 (9.0 to 17.7) | 12.9 (10.5 to 15.0) |
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| OS; PD-L1 (TC >=1%) Analysis Set Population | 14.6 (10.5 to 17.7) | 10.9 (9.1 to 13.5) | 12.3 (10.6 to 14.6) |
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| OS; FAS Population | 12.3 (10.1 to 14.9) | 11.2 (9.5 to 12.9) | 11.8 (10.5 to 13.3) |
The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy | 4.7 (3.1 to 6.3) | 3.9 (2.8 to 5.0) | 5.4 (4.6 to 5.8) |
The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| PFS; PD-L1 (TC >=1%) Analysis Set Population | 3.6 (2.8 to 4.2) | 2.8 (2.5 to 3.4) | 5.5 (4.9 to 5.7) |
The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| PFS; FAS Population | 2.8 (2.6 to 3.1) | 2.9 (2.6 to 3.4) | 5.4 (4.8 to 5.6) |
The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of Complete Response (CR) or Partial Response (PR). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
| percentage of participants | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population | 35.6 | 34.4 | 37.7 |
The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
| percentage of participants | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| ORR; PD-L1 (TC >=1%) Analysis Set Population | 26.5 | 25.3 | 33.6 |
The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
| percentage of participants | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| ORR; FAS Population | 22.2 | 24.7 | 30.1 |
The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population | NA (4.9 to NA) | NA (4.2 to NA) | 4.4 (2.9 to 7.2) |
The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| DoR; PD-L1 (TC >=1%) Analysis Set Population | NA (5.5 to NA) | NA (5.6 to NA) | 4.4 (2.8 to 8.4) |
The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| DoR; FAS Population | NA (5.5 to NA) | NA (4.7 to NA) | 4.3 (2.8 to 8.4) |
The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.
| percentage of participants | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population | 32.3 (24.8 to 39.9) | 25.8 (18.9 to 33.1) | 14.3 (8.4 to 21.7) |
The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.
| percentage of participants | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population | 27.0 (21.6 to 32.6) | 20.4 (15.7 to 25.5) | 14.9 (10.2 to 20.5) |
The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.
| percentage of participants | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| Percentage of Participants APF12; FAS Population | 22.5 (18.1 to 27.1) | 19.8 (15.6 to 24.4) | 13.8 (9.7 to 18.6) |
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population | 12.7 (9.4 to 16.1) | 10.9 (7.9 to 14.1) | 10.4 (9.0 to 12.5) |
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| PFS2; PD-L1 (TC >=1%) Analysis Set Population | 10.6 (8.0 to 12.7) | 9.4 (7.8 to 11.4) | 10.5 (9.4 to 11.7) |
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.
| months | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| PFS2; FAS Population | 9.3 (7.9 to 10.6) | 9.8 (8.8 to 11.4) | 10.1 (9.3 to 10.8) |
Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items with higher scores representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change is defined as an absolute change in the score from baseline of \>=10.
| units on a scale | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| EORTC QLQ-C30: Fatigue | 1.2 ± 1.83 | -1.1 ± 1.92 | 10.6 ± 2.34 |
| EORTC QLQ-C30: Appetite loss | -3.9 ± 2.24 | 2.4 ± 2.37 | 8.0 ± 2.83 |
| EORTC QLQ-LC13: Dyspnoea | 2.3 ± 1.51 | 0.8 ± 1.60 | 5.6 ± 1.90 |
| EORTC QLQ-LC13: Cough | -11.4 ± 1.88 | -5.9 ± 2.01 | -7.1 ± 2.54 |
| EORTC QLQ-LC13: Chest pain | 0.1 ± 1.71 | 1.6 ± 1.80 | 1.7 ± 2.04 |
Blood samples were collected to determine the serum concentration of durvalumab.
| microgram per milliliter (mcg/mL) | Durvalumab Monotherapy | Durvalumab + Tremelimumab |
|---|---|---|
| At Week 0: Pre-infusion | NA ± NA | NA ± NA |
| At Week 0: End of infusion | 484.5 ± 210.50 | 444.3 ± 150.29 |
| At Week 12: Pre-infusion | 139.5 ± 124.98 | 140.8 ± 146.25 |
| At Week 12: End of infusion | 625.3 ± 453.8 | 506.1 ± 231.89 |
| At Week 24: Pre-infusion | 163.0 ± 170.04 | 197.0 ± 228.79 |
| At Week 24: End of infusion | 598.2 ± 344.52 | 553.2 ± 193.33 |
| At follow-up Month 3 | 49.3 ± 132.54 | 41.4 ± 131.71 |
Blood samples were collected to determine the serum concentration of tremelimumab.
| mcg/mL | Durvalumab + Tremelimumab |
|---|---|
| At Week 0: Pre-infusion | NA ± NA |
| At Week 0: End of infusion | 22.6 ± 14.84 |
| At Week 12: Pre-infusion | 4.9 ± 4.16 |
| At Week 12: End of infusion | 24.8 ± 10.43 |
| At follow-up Month 3 | 0.5 ± 0.42 |
Blood samples were collected to determine the Cmax\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.
| mcg/mL | Durvalumab Monotherapy | Durvalumab + Tremelimumab |
|---|---|---|
| Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab | 625.3 ± 453.80 | 506.1 ± 231.89 |
Blood samples were collected to determine the Cmax\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.
| mcg/mL | Durvalumab + Tremelimumab |
|---|---|
| Cmax_ss of Tremelimumab | 24.8 ± 10.43 |
Blood samples were collected to determine the Ctrough\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.
| mcg/mL | Durvalumab Monotherapy | Durvalumab + Tremelimumab |
|---|---|---|
| Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab | 139.5 ± 124.98 | 140.8 ± 146.25 |
Blood samples were collected to determine the Ctrough\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.
| mcg/mL | Durvalumab + Tremelimumab |
|---|---|
| Ctrough_ss of Tremelimumab | 4.9 ± 4.16 |
Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against durvalumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
| Participants | Durvalumab Monotherapy | Durvalumab + Tremelimumab |
|---|---|---|
| ADA positive at any time | 17 | 14 |
| Treatment-emergent ADA positive | 8 | 8 |
| ADA positive at baseline and post-baseline | 3 | 1 |
| ADA positive at post-baseline only | 8 | 8 |
| ADA positive at baseline only | 6 | 5 |
| Treatment-boosted ADA | 0 | 0 |
| Persistent positive | 8 | 9 |
| Transient positive | 3 | 0 |
| nAb positive at any visit | 2 | 1 |
Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against tremelimumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
| Participants | Durvalumab + Tremelimumab |
|---|---|
| ADA positive at any time | 33 |
| Treatment-emergent ADA positive | 28 |
| ADA positive at baseline and post-baseline | 1 |
| ADA positive at post-baseline only | 28 |
| ADA positive at baseline only | 4 |
| Treatment-boosted ADA | 0 |
| Persistent positive | 25 |
| Transient positive | 4 |
| nAb positive at any visit | 25 |
Collected over From first administration of study treatment up to 90 days after last dose of durvalumab and tremelimumab or 30 days after last dose of SoC or date of initiation of the first subsequent therapy, whichever occurs first, approximately 3 years. All-cause mortality, from screening up to data cut-off date (approximately 3 years 1 month).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab Monotherapy | 278/374 (74.3%) | 131/369 (35.5%) | 335/369 (90.8%) |
| Durvalumab + Tremelimumab | 278/372 (74.7%) | 178/371 (48%) | 328/371 (88.4%) |
| SoC Chemotherapy | 297/372 (79.8%) | 112/352 (31.8%) | 332/352 (94.3%) |
| Event | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| PneumoniaInfections and infestations | 20/369 | 21/371 | 19/352 |
| AnaemiaBlood and lymphatic system disorders | 1/369 | 4/371 | 14/352 |
| DiarrhoeaGastrointestinal disorders | 2/369 | 12/371 | 6/352 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 5/369 | 9/371 | 1/352 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/369 | 6/371 | 8/352 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/369 | 7/371 | 0/352 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 2/369 | 7/371 | 0/352 |
| PancytopeniaBlood and lymphatic system disorders | 0/369 | 0/371 | 6/352 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/369 | 6/371 | 2/352 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 6/369 | 5/371 | 1/352 |
| Event | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy |
|---|---|---|---|
| NauseaGastrointestinal disorders | 46/369 | 78/371 | 143/352 |
| AnaemiaBlood and lymphatic system disorders | 36/369 | 33/371 | 136/352 |
| Decreased appetiteMetabolism and nutrition disorders | 73/369 | 89/371 | 78/352 |
| ConstipationGastrointestinal disorders | 62/369 | 59/371 | 83/352 |
| FatigueGeneral disorders | 65/369 | 80/371 | 80/352 |
| VomitingGastrointestinal disorders | 28/369 | 30/371 | 74/352 |
| DiarrhoeaGastrointestinal disorders | 51/369 | 74/371 | 41/352 |
| NeutropeniaBlood and lymphatic system disorders | 6/369 | 2/371 | 65/352 |
| PruritusSkin and subcutaneous tissue disorders | 42/369 | 67/371 | 17/352 |
| RashSkin and subcutaneous tissue disorders | 39/369 | 57/371 | 40/352 |
Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.
| Age, Continuous(years) | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy | Total |
|---|---|---|---|---|
| Mean | 63.2 ± 10.30 | 64.3 ± 9.52 | 63.6 ± 9.36 | 63.7 ± 9.74 |
| Sex: Female, Male(Participants) | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy | Total |
|---|---|---|---|---|
| Female | 118 | 106 | 122 | 346 |
| Male | 256 | 266 | 250 | 772 |
| Ethnicity (NIH/OMB)(Participants) | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 15 | 13 | 6 | 34 |
| Not Hispanic or Latino | 359 | 358 | 366 | 1083 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Durvalumab Monotherapy | Durvalumab + Tremelimumab | SoC Chemotherapy | Total |
|---|---|---|---|---|
| White | 243 | 249 | 243 | 735 |
| Black or African American | 3 | 3 | 4 | 10 |
| Asian | 125 | 118 | 120 | 363 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 2 | 2 |
| Other | 3 | 1 | 3 | 7 |
| Missing | 0 | 1 | 0 | 1 |
Showing the first 100 of 196 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2015 to primary completion in Oct 2018, 38 months.
Results were first posted in Nov 2019, 1 year 1 month after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 38 months is close to that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab
Carcinoma, Non-Small-Cell Lung →